SEATTLE, Sept. 14, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will be presenting at the 2016 Aegis Growth Conference. Robert W. Overell, Ph.D., president and chief executive officer, will provide an overview of the company and its development stage programs on Wednesday, September 21, 2016 at 3:30 p.m. PDT (6:30 p.m. EDT). The investor conference will be held from September 21-22, 2016 at the Encore at Wynn in Las Vegas.
A live audio webcast and replay will be available on the investor relations section of PhaseRx’s corporate website at www.phaserx.com and will be archived following the presentation for 90 days. Please connect to PhaseRx’s website several minutes prior to the start of the broadcast to ensure adequate time for any any software download that may be necessary.
About PhaseRx
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. PhaseRx’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The company’s i-ERT approach is enabled by its proprietary Hybrid mRNA TechnologyTM platform and is applicable to a significant number of inherited liver diseases. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Contacts:
Company & Media Contact:
Erin Cox
PhaseRx, Inc.
Head of Investor Relations
erin@phaserx.com
206.805.6306
Investor Contact:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
robert.uhl@westwicke.com
858.356.5932
Logo - http://photos.prnewswire.com/prnh/20160802/395011LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/phaserx-to-present-at-the-2016-aegis-growth-conference-300327655.html
SOURCE PhaseRx, Inc.
